Unravelling the functional significance of PCSK9

Current Opinion in Lipidology

Volumn 18, Issue 3, 2007, Pages 304-309

  Lambert, Gilles ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b HEART RESEARCH INSTITUTE   (Australia)

Author keywords

Familial hypercholesterolemia; Hypobetalipoproteinemia; LDL receptor; Proprotein convertase subtilisin kexin type 9

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

DNA POLYMORPHISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPOBETALIPOPROTEINEMIA; HYPOCHOLESTEROLEMIA; IN VITRO STUDY; ISCHEMIC HEART DISEASE; LIVER CELL; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPOPROTEINEMIAS; LIPOPROTEINS, LDL; MODELS, BIOLOGICAL; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

ANIMALIA;

EID: 34248366942     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3281338531     Document Type: Review

References (45)

1. Garuti R, Jones C, Li WP, et al. The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits. J Biol Chem 2005; 280:40996-41004.
2. Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006; 43:943-949.
3. Tosi I, Toledo-Leiva P, Neuwirth C, et al. Genetic defects causing familial hypercholesterolaemia: Identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic. Atherosclerosis 2006 Nov 7; [Epub ahead of print].
4. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34:154-156.
5. Lambert G, Krempf M, Costet P. PCSK9: a promising therapeutic target for dyslipidemias? Trends Endocrinol Metab 2006; 17:79-81.
6. Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004; 65:419-422.
7. Naoumova RP, Tosi I, Patel D, et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 2005; 25:2654-2660.
8. Sun XM, Eden ER, Tosi I, et al. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet 2005; 14:1161-1169.
9. Timms KM, Wagner S, Samuels ME, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004; 114:349-353.
10. Allard D, Amsellem S, Abifadel M, et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 2005; 26:497.
11. Pisciotta L, Oliva CP, Cefalu AB, et al. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis 2006; 186:433-440.
12. Shioji K, Mannami T, Kokubo Y, et al. Genetic variants in PCSK9 affect the cholesterol level in Japanese. J Hum Genet 2004; 49:109-114.
13. Chen SN, Ballantyne CM, Gotto AM Jr, et al. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 2005; 45:1611-1619.
14. Evans D, Beil FU. The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women. BMC Med Genet 2006; 7:66.
15. Kotowski IK, Pertsemlidis A, Luke A, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006; 78:410-422. This paper describes new missense mutations on PCSK9 associated with low plasma LDL levels in two large cohorts.
16. Yue P, Averna M, Lin X, Schonfeld G. The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum Mutat 2006; 27:460-466.
17. Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37:161-165.
18. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2006; Sep 19 [Epub ahead of print]. This study reported for the first time the dramatically low LDL cholesterol levels in a PCSK9 loss of function homozygous female.
19. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79:514-523. This report demonstrates that PCSK9 is secreted in the plasma and that loss of function mutations prevent either synthesis, trafficking or secretion of the mature PCSK9 protein.
20. Fasano T, Cefalu AB, Di Leo E, et al. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol 2006; 27:677-681.
21. Berge KE, Ose L, Leren TP. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 2006; 26:1094-1100.
22. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264-1272. Another breakthrough in PCSK9 genetics linking mutations in PCSK9 not only with reduced LDL but also with dramatically reduced incidence of cardiovascular disease over a 15-year period.
23. Topol EJ, Smith J, Plow EF, Wang QK. Genetic susceptibility to myocardial infarction and coronary artery disease. Hum Mol Genet 2006; 15 (Spec No 2):R117-R123.
24. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003; 100:928-933.
25. Bingham B, Shen R, Kotnis S, et al. Proapoptotic effects of NARC1 (=PCSK9), the gene encoding a novel serine proteinase. Cytometry A 2006; 69:1123-1131.
26. Poirier S, Prat A, Marcinkiewicz E, et al. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system. J Neurochem 2006; 98:838-850.
27. Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and Its Natural Mutants: Zymogen cleavage and effects on the LDL receptor and LDL cholesterol. J Biol Chem 2004; 279:48865-48875.
28. Maxwell KN, Soccio RE, Duncan EM, et al. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res 2003; 44:2109-2119.
29. Naureckiene S, Ma L, Sreekumar K, et al. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys 2003; 420:55-67.
30. Seidah NG, Khatib AM, Prat A. The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol Chem 2006; 387:871-877.
31. Horton JD, Shah NA, Warrington JA, et al.Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A 2003; 100:12027-12032.
32. Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, thegene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004; 24:1454-1459.
33. Costet P, Cariou B, Lambert G, et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 2006; 281:6211-6218. The authors provide a thorough analysis of how PCSK9 gene expression is regulated at the transcriptionnal level by insulin and cloning of the proximal promoter of PCSK9.
34. Lambert G, Jarnoux AL, Pineau T, et al. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology 2006; 147:4985-4995. This report establishes the first direct evidence for a role for PCSK9 in VLDL hepatic production through effects on the LDLr.
35. Lalanne F, Lambert G, Amar MJ, et al. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J Lipid Res 2005; 46:1312-1319.
36. Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 2004; 101:7100-7105.
37. Park SW, Moon YA, Horton JD. Posttranscriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004; 279:50630-50638.
38. Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 2005; 102:5374-5379.
39. Ouguerram K, Chetiveaux M, Zair Y, et al. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol 2004; 24:1448-1453.
40. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a postendoplasmic reticulum compartment. Proc Natl Acad Sci U S A 2005; 102:2069-2074.
41. Maxwell KN, Breslow JL. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. Curr Opin Lipidol 2005; 16:167-172.
42. Benjannet S, Rhainds D, Hamelin J, et al. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and posttranslational modifications. J Biol Chem 2006; 281:30561-30572. This study demonstrated that the mature PCSK9 form is degraded by two other proprotein convertases which result in its inactivation and that this phenomenon does not occur for at least two PCSK9 missense mutants, which explains the familial hypercholesterolemia phenotype of carriers.
43. Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006; 116:2995-3005. This elegant study unravelled the molecular mechanisms by which PCSK9 alters LDLr expression. It clearly demonstrated that PCSK9 acts both intracellularly and as a secreted protein and that it requires the LDLr and the ARH adaptor protein to be internalized and subsequently enhance LDLr degradation, in vitro and in vivo.
44. Grozdanov PN, Petkov PM, Karagyozov LK, Dabeva MD. Expression and localization of PCSK9 in rat hepatic cells. Biochem Cell Biol 2006; 84:80-92.
45. Cameron J, Holla OL, Ranheim T, et al. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 2006; 15:1551-1558.